Search results
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Zacks via Yahoo Singapore Finance· 1 week agoThe FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat...
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
Zacks via Yahoo Singapore Finance· 4 weeks agoIt was a busy week for the biotech sector, with numerous data presentations by biotech companies at...
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
Benzinga via Yahoo Singapore Finance· 1 month agoOn Thursday, the European Commission granted marketing authorization under exceptional circumstances...
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Zacks via Yahoo Singapore Finance· 1 month agoBiogen BIIB announced that the European Commission (EC) has granted marketing approval to Qalsody...
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Zacks via Yahoo Singapore Finance· 2 months agoShares of Ionis Pharmaceuticals IONS and Biogen BIIB lost at least 2% in market cap on Thursday...
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Zacks via Yahoo Singapore Finance· 2 months agoIonis Pharmaceuticals IONS reported a loss of 98 cents per share for first-quarter 2024, which was...
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
Zacks via Yahoo Singapore Finance· 3 months agoIonis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is...
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
Zacks via Yahoo Singapore Finance· 6 months agoVoyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and...
Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates
Zacks via Yahoo Singapore Finance· 8 months agoIonis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company...
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
Zacks via Yahoo Singapore Finance· 11 months agoIonis Pharmaceuticals IONS reported a loss of 60 cents per share for second-quarter 2023, which was...